Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.
Doccla Secures $45.9M to Scale Virtual Ward Solutions Across Europe
What You Should Know: – Doccla, a London-based provider of virtual ward and remote patient monitoring services, announced raises $45.9M (£35M) Series B funding round
September 3, 2024